(NASDAQ: SLDB) Solid Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.83%.
Solid Biosciences's earnings in 2026 is -$207,099,000.On average, 15 Wall Street analysts forecast SLDB's earnings for 2026 to be -$193,112,654, with the lowest SLDB earnings forecast at -$251,035,727, and the highest SLDB earnings forecast at -$174,509,075. On average, 15 Wall Street analysts forecast SLDB's earnings for 2027 to be -$190,935,981, with the lowest SLDB earnings forecast at -$251,142,952, and the highest SLDB earnings forecast at -$136,229,665.
In 2028, SLDB is forecast to generate -$142,341,503 in earnings, with the lowest earnings forecast at -$230,126,806 and the highest earnings forecast at -$54,041,520.